医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GVK BIO Announces the Promotion of Sudhir Kumar Singh to Chief Operating Officer and Appointment of Ramesh Subramanian as the New Chief Commercial Officer of GVK BIO

2019年09月04日 PM08:00
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

GVK BIO, a leading global Contract Research and Development Organisation (CRDO), is pleased to announce the promotion of Sudhir Kumar Singh, Ph.D., to the position of Chief Operating Officer and the appointment of Ramesh Subramanian, Ph.D., as its new Chief Commercial Officer.

Sudhir joined GVK BIO in 2013 as a Senior Vice President and has been driving the Discovery Research business. He has been successful in integrating best practices in Chemistry, Biology and Chemical Development to be able to meet the key business goals.

“Sudhir, over the years has bought in a transformational change in the Discovery Research vertical and has been instrumental in sustaining GVK BIO’s leadership in the Chemistry business in terms of delivery and profitability,” commented Manni Kantipudi, Director & CEO, GVK BIO. “In his new role, Sudhir will focus on leading and building a customer centric culture, strengthen our rapidly growing development and manufacturing footprint, while ensuring safety and compliance in the work environment.”

“Additionally, I am pleased to welcome Ramesh Subramanian to the GVK BIO management team. Ramesh brings with him deep industry knowledge in the various verticals of GVK BIO. I look forward to working with him towards our stated goal of making GVK BIO the ‘partner of choice’ for Life Science companies seeking to accelerate their R&D. In his role, Ramesh will be responsible for all Business Development, Sales, Marketing, and Corporate Development activities.”

Ramesh Subramanian brings over 20 years of global experience in building businesses across Asia, Europe, and North America, raising venture capital, implementing transformational strategies, driving M&A, and managing cross-border alliances.

Prior to joining GVK BIO, Ramesh served as the Senior Vice President, and was a part of the management team at Piramal Pharma Solutions. Over his career, Ramesh has been part of management teams at Chemizon – a firm he led from start-up to a successful entry into the equity markets – Jubilant Life Sciences, and XL Advisors. Ramesh also has held key leadership roles at SK Capital Partners/Ascend Performance Materials and Johnson Matthey.

Ramesh has a Ph.D. in Chemical Engineering from West Virginia University, a B.Tech. in Chemical Engineering from IIT-Varanasi, and an MBA in Finance from The Wharton School, University of Pennsylvania.

About GVK BIO

GVK BIO, a leading Contract Research & Development Organization servicing the global Biopharma industry; is headquartered in Hyderabad, India with operations in five sites including California, USA. Established in 2001, GVK BIO has over 18 years of experience across the Research and Development value chain with a focus on speed and quality while ensuring safety and compliance. GVK BIO’s team of over 2300 highly qualified scientists, backed by a no-conflict business model, well-defined and scalable processes, modern facilities, and a strong customer-centric partnering approach, focus on bringing its customers’ products to market. www.gvkbio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190904005361/en/

CONTACT

Dorothy Paul

Dorothy.paul@gvkbio.com

Phone: +91 9908130236

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作